Pipelines Report 2023: innovation and diversification – PharmaLive
Idiopathic Pulmonary Fibrosis (IPF) Market Size, Share Analysis, Growth Trends And Forecast 2023 – 2030
According to the DataM market research report, the Global Idiopathic Pulmonary Fibrosis Market size reached US$ 2,184.4 million in 2022 and is expected to witness lucrative growth by reaching up to US$ 4,614.3 million by 2030. The global idiopathic pulmonary fibrosis market is projected to exhibit a CAGR of 10.1% during the forecast period (2023-2030). The most important market trend is the rising demand for robust pipeline medications.
The global market for idiopathic pulmonary fibrosis is driven by factors such as the increasing clinical trials of IPF drugs, the rising aging population, the availability of approved therapies, the expanding pipeline and investigational drugs, rising awareness & early diagnosis, and advances in research techniques.
The global idiopathic pulmonary fibrosis market is segmented on the basis of treatment, end-user, and region. North America holds the 40.2% marketplace percentage for the idiopathic pulmonary fibrosis marketplace in 2022 because of the excessive sickness burden and availability of authorized therapies.
The major global players include Roche Holdings AG, Boehringer Ingelheim GmbH, Genentech Inc., FibroGen Inc., Galapagos NV, MEDICINOVA INC., Bristol Myers Squibb Company, Biogen Inc., AstraZeneca PLC, and Novartis International AG.
For more details on this report Request for Sample: https://www.Datamintelligence.Com/download-sample/idiopathic-pulmonary-fibrosis-market
Market Drivers:The availability of approved therapies for the treatment of idiopathic pulmonary fibrosis is the major factor driving the market share during the forecast period. The approval of antifibrotic medications, such as pirfenidone and nintedanib, demonstrated efficacy in slowing disease progression and improving patient outcomes. The availability of approved therapies has not only provided treatment options but also increased the overall interest and investment in IPF research and development.
Market Restraints:The side effects of the treatment and the limited treatment options associated with idiopathic pulmonary fibrosis are the major factors expected to hamper the market growth. Despite the availability of approved therapies, the treatment options for IPF are still limited. Antifibrotic drugs, such as pirfenidone and nintedanib, are the mainstay of treatment, but they are not curative and only slow disease progression, which can limit the treatment options for patients.
Market Opportunities:Early and accurate diagnosis of IPF is crucial for initiating timely treatment and improving patient outcomes. Advancements in imaging techniques, such as high-resolution computed tomography (HRCT) and biomarker testing, can aid in the early detection and differentiation of IPF. Companies that develop improved diagnostic tools and techniques can capture a significant market share.
View Full Report: https://www.Datamintelligence.Com/research-report/idiopathic-pulmonary-fibrosis-market
COVID-19 Impact AnalysisThe COVID-19 pandemic has had a significant impact on the idiopathic pulmonary fibrosis market. COVID-19 primarily affects the respiratory system, and individuals with pre-existing lung conditions, including IPF, are at a higher risk of developing severe illness if they contract the virus. The heightened vulnerability of IPF patients to COVID-19 has led to increased attention to their care, management, and protection.
The COVID-19 pandemic highlighted the importance of respiratory health and increased awareness about lung diseases, including IPF. This heightened focus on respiratory health may drive attention, research, and funding toward IPF and other pulmonary fibrosis conditions.
Russia-Ukraine Conflict AnalysisThe Russia-Ukraine war significantly impacted the idiopathic pulmonary fibrosis market growth. The conflict may affect international collaborations and research initiatives involving Russian and Ukrainian healthcare institutions, pharmaceutical companies, and academic organizations.
Collaboration and exchange of scientific knowledge are crucial for advancing IPF research and developing new therapies. Political tensions and restrictions on collaboration can impede progress and hinder the exchange of expertise and resources, leading to a negative impact on the idiopathic pulmonary fibrosis market globally.
Recent Developments in the IndustryAs per the research analysis, the global idiopathic pulmonary fibrosis market is segmented by treatment into drugs, oxygen therapy, pulmonary rehabilitation, lung transplant, and others; by end-user into hospitals, clinics, and others.
Antifibrotic drugs, such as pirfenidone and nintedanib, have gained wide acceptance and are considered the standard of care for IPF. These medications have been extensively studied in clinical trials and have been shown to slow the decline in lung function and prolong survival. The high adoption of antifibrotic medications by healthcare professionals contributes to the dominance of the drugs segment.
Geographical AnalysisThe global idiopathic pulmonary fibrosis market is segmented into North America, Europe, South America, Asia Pacific, and Middle East & Africa.
North America Idiopathic Pulmonary Fibrosis MarketNorth America holds the 40.2% market share for the idiopathic pulmonary fibrosis market in 2022 due to the high disease burden and availability of approved therapies. North America has a relatively high prevalence of IPF compared to other regions. The aging population, environmental factors, and genetic predisposition contribute to the increased disease burden in this region.
Competitive Landscape:The major global players include Roche Holdings AG, Boehringer Ingelheim GmbH, Genentech Inc., FibroGen Inc., Galapagos NV, MEDICINOVA INC., Bristol Myers Squibb Company, Biogen Inc., AstraZeneca PLC, and Novartis International AG.
Suggestions for Related Report
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query with regard to the scope offered will be addressed within 24- 48 hours.
3) An Excel sheet with market numbers will be provided separately.
The Full Report has the below insights:
The report will provide access to approximately 61 market data tables, 64 figures and close to 180 pages.
About Us:
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you.
We encompass a multitude of Syndicate Reports & Customized Reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
What Is Idiopathic Pulmonary Fibrosis?
Medically reviewed by Susan Russell, MD
Idiopathic pulmonary fibrosis is a severe, chronic lung disease. It involves lung inflammation and/or scarring of your lungs' alveoli, or air sacs. The scarring causes stiffness in your lungs. This affects their ability to absorb oxygen from the air, making breathing difficult.
The causes of this illness are not fully known. As a result, this disease is called idiopathic, meaning it has no known cause. However, having certain risk factors can make you more likely to get the disease.
Lung damage caused by this disease cannot be changed. The illness becomes worse over time, making it harder to breathe. Treatment can help improve symptoms and slow the progress of the damage.
This article describes idiopathic pulmonary fibrosis symptoms, causes, diagnosis, treatment, and outlook.
Types of Idiopathic Pulmonary FibrosisIdiopathic pulmonary fibrosis is one of over 200 different types of interstitial lung disease (ILD), a condition that results in inflammation and scarring of the interstitium, a system of tissues that run through your lungs.
The impact of the disease makes the lung tissue stiff and thick. While other idiopathic types of interstitial lung disease exist, idiopathic pulmonary fibrosis is the most common.
Idiopathic pulmonary fibrosis is broken down into stages of illness. These stages are considered mild, severe, or advanced based on the results of pulmonary function tests.
A more specific classification system for idiopathic pulmonary fibrosis includes the following:
Stage 1: A recently diagnosed person with idiopathic pulmonary fibrosis
Stage 2: A person with idiopathic pulmonary fibrosis who needs oxygen with activity but not while at rest
Stage 3: A person with idiopathic pulmonary fibrosis who needs oxygen 24 hours a day, with activity, at rest, and during sleep
Stage 4: A person with idiopathic pulmonary fibrosis who needs advanced oxygen treatment, such as high-flow oxygen, or has progressed to the state of which a portable delivery system is inadequate for their oxygen needs
Story continues
Learn More: What Are the Types of Fibrosis?
Idiopathic Pulmonary Fibrosis SymptomsIdiopathic pulmonary fibrosis symptoms can vary by individual and can include the following:
Tachypnea (rapid, shallow breathing)
Dyspnea (shortness of breath) that begins during exercise and worsens to occur even at rest
Chronic dry cough that lasts longer than eight weeks and worsens to repeated, uncontrollable coughing episodes
Aching joints and muscles
Fatigue
Unintended weight loss
A general feeling of being unwell
Clubbed fingers and nails (widening and rounding of soft tissue around your fingernails and toenails)
Learn More: Pulmonary Fibrosis vs. Cystic Fibrosis: What Are the Differences?
CausesWhile the cause is unknown, idiopathic pulmonary fibrosis often occurs in people who have one of the following comorbidities (simultaneous disease):
Having one or more of the following factors can increase your chances of developing idiopathic pulmonary fibrosis with or without another disease present:
Male sex
Being in your 60s or 70s
Smoking
A first-degree relative, such as a parent or sibling, with idiopathic pulmonary fibrosis
Exposure to hazardous materials such as asbestos or silica
Learn More: Causes and Risk Factors of Pulmonary Fibrosis
DiagnosisThe diagnosis of idiopathic pulmonary fibrosis can be difficult. Since this disease is rare, it may not be familiar to many healthcare providers. In addition, many symptoms of idiopathic pulmonary fibrosis are also present in other lung diseases. As a result, many people may not get an accurate diagnosis until the disease progresses and symptoms become more specific and harmful with time.
The diagnosis of idiopathic pulmonary fibrosis typically requires more than one test. The following tests are commonly used:
Medical Examination
A medical examination involves a physical exam using a stethoscope to listen to your lungs. It also includes a discussion of the type, duration, and extent of your symptoms and information about your family history. A discussion of your risk factors and other medical conditions is also included.
Imaging Tests
The following imaging tests may be used to look for scarring in your lungs:
Chest X-ray: Uses small amounts of electromagnetic radiation to create images of your lungs and other internal organs
Computed tomography (CT) scan: Uses multiple X-rays to create a three-dimensional (3D) image of your lungs
Bronchoscopy
A bronchoscopy uses a bronchoscope (a type of endoscope made up of a thin tube with a light and camera on the end) to examine your airways and lungs. During the procedure, the bronchoscope is inserted into your nose, down through your trachea (windpipe), and into your lungs to collect a small sample of lung tissue or fluid for analysis.
Bronchoalveolar Lavage
A bronchoalveolar lavage removes fluids from the lower part of your respiratory tract to analyze the fluid for signs of infection or bleeding.
Pulmonary Function Tests
Pulmonary function tests can help diagnose idiopathic pulmonary fibrosis and distinguish it from other lung diseases. These tests include the following:
Spirometry: Measures how much air you can breathe in and out of your lungs and how fast and easily you can exhale out
Lung diffusion test: Measures how well carbon dioxide and oxygen are diffused, or transferred, between your lungs and blood
Lung plethysmography test: Determines how much air your lungs can hold
Blood Tests
Blood tests can detect signs of an autoimmune disease or environmental factors contributing to your breathing problems.
Lung Biopsy
A lung biopsy (removing a sample tissue for evaluation in a lab) may be used when the results of other procedures do not provide the data necessary to make a definitive diagnosis. A lung biopsy can be done via fine needle aspiration or as an open biopsy using an incision.
TreatmentTreatment for idiopathic pulmonary fibrosis can slow disease progression and help your lungs work better. The type of treatment you receive depends on several factors that include your age, the presence of unrelated illnesses, your symptoms, and the severity and stage of your disease.
Treatment for idiopathic pulmonary fibrosis can involve any of the following:
Medications
The following antifibrotic medications are used to help slow the rate of scar tissue that causes scarring in the lungs and help patients achieve a better quality of life with idiopathic pulmonary fibrosis:
Esbriet (pirfenidone)
Ofev (nintedanib)
Lifestyle Changes
Lifestyle changes can involve a wide range of approaches for managing symptoms. These can include the following:
Quit smoking.
Avoid situations or environments where breathing is more difficult due to poor air quality, pollution, or dust.
Remain active with regular physical activity to maintain your strength and lung function.
Address anxiety and depression.
Eat a heart-healthy diet.
Receive vaccinations for pneumonia and influenza.
Oxygen Therapy
Oxygen therapy is administering supplemental oxygen to increase oxygen levels to healthy, normal levels. This can help you achieve the following:
Pulmonary Rehabilitation
Pulmonary rehabilitation is a multifaceted type of lung therapy. It can include exercises and education to help you achieve the following:
Lung Transplant
Occasionally, a lung transplant may be the recommended course of treatment. It is typically reserved for those with a severe form of the disease that has not responded to other treatments. A lung transplant is most often used to treat patients without significant complications. People who receive a lung transplant must pass a stringent evaluation process to determine the potential for success of the procedure.
Learn More: Treatment Options for Idiopathic Pulmonary Fibrosis
PrognosisIdiopathic pulmonary fibrosis is a rare disease that varies significantly from person to person. This can make a prognosis hard to determine. While some people may rapidly decline in health and quality of life, others experience periods of relative calm followed by acute deterioration.
Comorbidity can significantly impact the prognosis of your idiopathic pulmonary fibrosis. Having another disease simultaneously can contribute to delays in diagnosing and treating idiopathic pulmonary fibrosis. This can advance the loss of quality of life and worsen outcomes.
CopingEveryone copes with chronic illness differently. Many people benefit from palliative care, also known as supportive care. This type of care focuses on relieving and preventing symptoms that cause discomfort.
Palliative care aims to improve your quality of life with idiopathic pulmonary fibrosis. It usually involves a team approach that includes physicians, nurses, social workers, psychologists, pharmacists, and other healthcare professionals.
Palliative care does not mean you can't also receive curative care, which can involve treatment, consideration for lung transplantation, and participation in idiopathic pulmonary fibrosis research studies.
You may also benefit from the following strategies when coping with this disease:
Participation in an in-person or online support group in which you can discuss your situation with others who have similar first-hand experiences
Education through healthcare professionals or organizations dedicated to the treatment of pulmonary diseases
Following sources such as blogs, podcasts, and social media groups that address the challenges of coping with chronic lung disease
Idiopathic pulmonary fibrosis is a rare but severe type of chronic lung disease. The illness can have an extreme medical and psychological impact. The effect stiffens and thickens lung tissue, making it harder to breathe during movement. As the condition advances, it can also cause breathing hard during rest and sleep.
The causes of this disease are not fully known, though having certain risk factors can make you more likely to develop it. With symptoms common to many other types of lung disease, this illness can be hard to diagnose. It can sometimes take years if the disease moves slowly and its impact gradually.
Treatment can help reduce symptoms, but the damage caused cannot be improved. The prognosis is usually poor. In severe cases, lung replacement may be a treatment option after other failed therapies.
Novel Imaging Agent Allows For Earlier Detection Of Progressive Pulmonary Fibrosis
A newly developed PET imaging agent, 64Cu-GPVI-Fc, can non-invasively identify pulmonary fibrosis in its early stages, reducing the need for unnecessary biopsies and allowing patients to begin treatment sooner. This research was published in the June issue of the Journal of Nuclear Medicine.
Pulmonary fibrosis is a fatal disease with a life expectancy of three to five years after diagnosis. While it is relatively easy to diagnose in its advanced stages, it is difficult to identify pulmonary fibrosis is its earliest stages when treatment of the disease is most effective.
"Currently, routine clinical diagnosis of pulmonary fibrosis relies on breathing tests and visualizing the changes in lung structure with CT, but this anatomical information is often not sufficient to identify early signs of the disease," said Nicolas Bézière, Ph.D., head of Imaging of Infection and Inflammation at the Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy at Eberhard Karls University of Tübingen in Tübingen, Germany. "Molecular imaging of the biomarkers of pulmonary fibrosis could lead to earlier detection and better monitoring, as well as provide a novel way to assess treatment efficacy."
In patients with pulmonary fibrosis, remodeling of lung tissue occurs through increased deposition of extracellular matrix fibers, such as collagen I-III, fibronectin and fibrinogen. In the study, researchers used 64Cu-GPVI-Fc, an imaging agent that targets these extracellular matrix fibers, to identify pulmonary fibrosis in a mouse model. These results were compared to histological findings, as well as to imaging with 18F-FDG PET.
64Cu-GPVI-Fc showed significant uptake in lungs with pulmonary fibrosis, which matched histological results. Contrary to the findings of the 18F-FGD PET imaging, 64Cu-GPVI-Fc uptake was entirely linked to pulmonary fibrosis activity in the lung tissues and did not identify any inflammation.
"In a disease with such a large impact on the patients' quality of life and with such a reduced life expectancy after diagnosis, it is critical that proper diagnosis and treatment follow-up methods are specific and sensitive enough that optimal medical care can be given. We believe 64Cu-GPVI-Fc takes us one step closer to personalized medicine for pulmonary fibrosis," noted Bézière.
He continued, "We hope that this approach based on a tracer targeting a range of extracellular matrix fibers will provide a new way to view the 'complete picture' of pulmonary fibrosis progression and act as a new method to monitor treatment efficacy. Furthermore, fibrosis is not limited to the lungs, it can develop in other organs and lead to a loss of their function. Thus, we can foresee the transfer of this approach to other fibrotic diseases."
More information: Simon Isser et al, Radiolabeled GPVI-Fc for PET Imaging of Multiple Extracellular Matrix Fibers: A New Look into Pulmonary Fibrosis Progression, Journal of Nuclear Medicine (2023). DOI: 10.2967/jnumed.122.264552
Citation: Novel imaging agent allows for earlier detection of progressive pulmonary fibrosis (2023, June 21) retrieved 23 June 2023 from https://medicalxpress.Com/news/2023-06-imaging-agent-earlier-pulmonary-fibrosis.Html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Comments
Post a Comment